您的位置: 印度药房网 > 医药大数据 > 白血病 >
伊马替尼

印度伊马替尼

资料发布时间:2018-10-30 14:50:00 最后更新时间:2020-04-18 21:42:46

【药品简介】 伊马替尼(格列卫,Imatinib),酪氨酸激酶抑制剂,是一种小分子蛋白激酶抑制剂,它具有阻断一种或多种蛋白激酶的作用。

【适应症状】 伊马替尼,处方药。用于治疗费城染色体阳性的慢性髓性白血病(Ph+CML)的慢性期、加速期或急变期;用于治疗难治复发成人费城染色体阳性的急性淋巴细胞白血病(Ph+ALL);不能手术切除和/或发生转移的恶性胃肠道间质肿瘤(GIST)的成人患者。

【 药品别名 】 格列卫 甲磺酸伊马替尼 Imatinib

印度伊马替尼(格列卫 甲磺酸伊马替尼 Imatinib)价格,正品图片,治疗白血病药物, 购买伊马替尼请到印度药房官方网站进行购买 【印度药房大全目录】

播放/暂停

印度全球药房排名

【印度伊马替尼说明书,怎么吃?】

【伊马替尼(格列卫,Imatinib)作用机制】

磺酸伊马替尼在体内外均可在细胞水平上抑制Bcr-Abl酪氨酸激酶,能选择性抑制Bcr-Abl阳性细胞系细胞、Ph染色体阳性的慢性粒细胞白血病和急性淋巴细胞白血病病人的新鲜细胞的增殖和诱导其凋亡。此外,甲磺酸伊马替尼还可抑制血小板衍化生...
 
【副作用】   

多数患者在服用甲磺酸伊马替尼期间会出现一些不良反应,但绝大多数属轻到中度。考虑到疾病本身也会产生症状,常难以明确他们的因果关系。临床试验过程中,因药物相关的不良反应而停药者,在α-干扰素治疗失败的慢粒慢性期患者中仅占1%
给药方法】
 
治疗应由对恶性肿瘤患者有治疗经验的医师进行。甲磺酸伊马替尼应在进餐时服用,并饮一大杯水,以使胃肠道紊乱的风险降到最小。通常成人每日一次,每次400mg或600mg,以及日服用量800mg即400mg剂量每天2次(在早上及晚上)。儿童和青少年每日一次或分两次服用(早晨和晚上)。不能吞咽药片的患者(包括儿童),可以将药片分散于不含气体的水或苹果汁中(100mg片约用50ml,400mg约用200ml)。应搅拌混悬液,一旦药片崩解完全应立即服用。只要患者持续受益,本品治疗应持续进行。 推荐的起始治疗剂量:400mg/天
 
在治疗后未能获得满意疗效,如果没有严重药物不良反应的话,剂量可考虑从400mg/天增加到600mg/天或800mg/天
 
格列卫是一种口服片剂,宜在每日最大餐量时服用,并饮一大杯水

 除非患者有吞咽困难的症状,否则不应将药物掰开或压碎。如果出现这种情况,可将药片溶于一杯水或苹果汁中。
伊马替尼


【伊马替尼(格列卫,Imatinib)注意事项】
 
如治疗过程中出现严重非血液学不良反应(如严重水潴留),宜停药,直到不良反应消失,随后再根据该不良反应的严重程度调整剂量。
 
如胆红质升高超过正常范围上限3倍或转氨酶升高超过正常范围上限5倍,宜停药,直到上述指标分别降到正常范围上限的1.5或2.5倍以下。
 
加速期或急变期 :如果出现严重中性粒细胞和血小板减少(中性粒细胞<0.5×109/L和/或血小板<10×109/L,建议剂量减少到400 mg/日。如果血细胞持续减少2周,则进一步减少剂量到300 mg/日,如血细胞持续减少4周,宜停药,直到中性粒细胞≥ (greater than or equal to) 1.0×109/L和血小板≥ (greater than or equal to) 20×109/L。再用时剂量为300 mg/日。
 
当中性粒细胞<1.0×109/L和/或血小板<50×109/L时宜停药,仅在中性粒细胞≥ (greater than or equal to) 1.5×109/L和血小板≥ (greater than or equal to) 75×109/L时再恢复用药,剂量为400 mg/日,如中性粒细胞或血小板重新减少到上述数值时,再恢复用药时剂量减至300 mg/日。
 
尚无18岁以下患者使用甲磺酸伊马替尼治疗的安全性和有效性临床资料。
 
有肝功能损害者甲磺酸伊马替尼的血浆浓度可以升高,因此这些患者用本药时要谨慎,目前尚无肝功能损害患者使用甲磺酸伊马替尼的临床资料,无法提出剂量调整的建议。
 
已知肌酐清除率可随年龄老化而降低,而年龄对甲磺酸伊马替尼的药代动力学无明显影响,由于尚未在肾功能损害患者中进行过临床试验,故无法提出剂量调整的建议。
 
对本药活性物质或任何赋形剂成份过敏者禁用。孕妇及哺乳期妇女用药禁用。

伊马替尼(格列卫,Imatinib)英文说明
Imatinib mesylate uses

Imatinib mesylate is used in the treatment of blood cancer (chronic myeloid leukaemia), Blood cancer (Acute lymphocytic leukemia) and gastrointestinal stromal tumour.

How imatinib mesylate works
I
matinib mesylate is an anti-cancer medication. A protein enzyme, bcr-abl tyrosine kinase, responsible for the growth of abnormal proliferation of cancer cells. This medicine inhibits the proliferation and induces apoptosis (planned cell death) in bcr-abl positive cells (cancer cells). This is how it works to stop or slow the spread of cancer.

Common side effects of imatinib mesylate

Nausea, Rash, Vomiting, Musculoskeletal (bone, muscle or joint) pain, Edema (swelling), Abdominal pain, Fatigue, Diarrhea, Muscle cramp

Imatinib

生物活性

产品描述

matinib is an inhibitor of the receptor tyrosine kinases c-Abl, Bcr-Abl, PDGFR, and c-Kit (IC50: 600/100/100 nM).

靶点活性

c-Kit,100 nM (cell free)

PDGFR,100 nM (cell free)

v-Abl,600nM

体外活性

Imatinib (STI 571) inhibited c-kit autophosphorylation, activation of mitogen-activated protein (MAP) kinase, and activation of Akt without altering total protein levels of c-kit, MAP kinase, or Akt. The concentration that produced 50% inhibition for these effects was approximately 100 nmol/L. STI 571 also significantly decreased SLF-dependent growth of M-07e cells in a dose-dependent manner and blocked the antiapoptotic activity of SLF [1]. Imatinib mesylate had a more similar effect on Bcr/Abl- and c-Kit–dependent proliferation, with an IC50 of 19 nM in R10(-) cells and 82 nM in MO7e cells growing in the presence of SCF (KL, Kit ligand), respectively [2]. STI571 inhibited tyrosine phosphorylation and cell growth of Ba/F3 cells expressing BCR/ABL, TEL/ABL, TEL/PDGFbetaR, and TEL/ARG with an IC(50) of approximately 0.5 microM in each case, but it had no effect on untransformed Ba/F3 cells growing in IL-3 or on Ba/F3 cells transformed by TEL/JAK2 [3].

体内活性

Imatinib (25 mg/kg/day, p.o.) significantly reduced the endometriosis score compared to normal saline. It significantly decreased the ovarian follicle number compared to normal saline. The CD117 staining score of rats administered imatinib was significantly lower than that of the rats received normal saline [4]. After intraperitoneal injection of STI571, it has 80%, 40% and 78% growth inhibition of SCLC6, SCLC61, and SCLC108 tumors, respectively, without any significant inhibition of SCLC74 tumor growth [5].

激酶实验

PDGF receptor kinase activity: PDGF receptor is immunoprecipitated from BALB/c 3T3 cell extracts with rabbit antiserum to the murine PDGF receptor for 2 hours on ice. Protein A-Sepharose beads are used to collect the antigen-antibody complexes. The immunoprecipitates are washed twice with TNET (50 mM Tris, pH 7.5, 140 mM NaCl, 5 mM EDTA, 1% Triton X-100), once with TNE (50 mM Tris, pH 7.5, 140 mM EDTA), and once with kinase buffer (20 mM Tris, pH 7.5,10 mM MgCl2). After stimulation with PDGF (50 ng/mL) for 10 minutes at 4 °C, different concentrations of drug are added to the reaction mixture. PDGF receptor kinase activity is determined by incubation with 10 μCi [7-33P]-ATP and l μM ATP for 10 minutes at 4 °C. Immune complexes are separated by SDS-PAGE on 7.5% gels.

细胞实验

M-07e cells were grown in serum-free RPMI 1640 at 37°C for approximately 18 hours before they were incubated for 90 minutes in the presence of various concentrations of STI 571. The cells were then pelleted and resuspended in 1 mL RPMI 1640. STI 571 was added to each tube to achieve the same concentration used during the 90 minutes of preincubation. The cells were then incubated with inhibitor and growth factor (SLF or GM-CSF) for 15 minutes at 37°C. Subsequently, the cell pellets were lysed with 100 to 250 μL of protein lysis buffer (50 mmol/L Tris, 150 mmol/L sodium chloride, 1% NP-40, and 0.25% deoxycholate, with addition of the inhibitors aprotinin, leupeptin, pepstatin, phenylmethyl sulfonyl fluoride, and sodium orthovanadate). Western immunoblot analysis was performed as previously described.41Experiments with HMC-1 cells were performed in the same way except that neither SLF nor GM-CSF was added [1].

细胞系: BON-1 cells and NCI-H727 cells

动物实验

Swiss mice (nu/nu, female), weighing 30 g, 6 – 8 weeks old, were bred in the animal facilities, maintained under specific pathogen-free conditions with artificial lighting (12 hr light/12 hr dark cycle) and fed a regular diet and water ad libitum. For therapeutic trials, the tumor-bearing mice were randomly divided into equivalent groups of 5 to 12 animals and mice were treated as soon as the xenografted tumors reached a diameter of 5 mm (or a tumor volume of approximately 60 mm^3). Four different human tumors were used: the SCLC6, SCLC61, SCLC 74 and SCLC108 small cell lung cancers. STI571 was administered at a total dosage of 70 or 100 mg/kg per day in 1 or 2 intraperitoneal injections, with or without etoposide plus ifosfamide or topotecan. STI571 was diluted in 150 l of H2O and administered on different days, as indicated. Etoposide and ifosfamide were diluted in 200 l of 0.9% sodium chloride, and topotecan was diluted in 150 l of 0.9% sodium chloride. The control group received injections according to the same schedule as experimentally treated mice. All mice were weighed once weekly. Tumor growth was monitored by measuring 2 perpendicular diameters with calipers. Tumor volume (V) and the relative tumor volume (RTV) were calculated as: V = a^2 × b/2, where a is the width (large diameter) and b the length (small diameter) of the tumor in millimeters, and RTV = Vx/Vi, where Vx is the mean tumor volume in cubic millimeters at any given time and Vi is the mean initial tumor volume in cubic millimeters at the start of treatment. Mice were ethically sacrificed when the tumor volume reached 2,500 mm^3 [5].

动物模型:SCLC6, SCLC61, SCLC 74 and SCLC108 small cell lung cancers are injected into Swiss mice (nu/nu, female).

化学信息

分子量

493.60

分子式

C29H31N7O

CAS

152459-95-5

溶解度

DMSO: 66.9 mM

( < 1 mg/ml refers to the product slightly soluble or insoluble )

储存条件

store at -80°C

备注

For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.

配制溶液

  1 mg 5 mg 10 mg
1 mM 2.026 ml 10.13 ml 20.259 ml
5 mM 0.405 ml 2.026 ml 4.052 ml
10 mM 0.203 ml 1.013 ml 2.026 ml
50 mM 0.041 ml 0.203 ml 0.405 ml
参考文献
 
1. Heinrich MC, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000 Aug 1;96(3):925-32.
2. Wolff NC, et al. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Blood. 2005 May 15;105(10):3995-4003. Epub 2005 Jan 18.
3. Okuda K, et al. ARG tyrosine kinase activity is inhibited by STI571.Blood. 2001 Apr 15;97(8):2440-8
4. Yildiz C, et al. Effect of imatinib on growth of experimental endometriosis in rats. Eur J Obstet Gynecol Reprod Biol. 2016 Feb;197:159-63.
5. Decaudin D, et al. In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy. Int J Cancer. 2005 Feb 20;113(5):849-56.
注:本站伊马替尼(格列卫 甲磺酸伊马替尼 Imatinib)药品说明,价格,正品图片均来自于官方,伊马替尼如何服用请尊医嘱。如需药品请到正规印度药房进行购买
上一篇:没有了 下一篇:马法兰
伊马替尼相关药品
伊马替尼
伊马替尼

处方药。用于治疗费城染色体阳性的慢性髓性白血病(Ph+CML)的慢性期、加速期或急变期;用于治疗难治复发成人费城染色体阳性的...

马法兰
马法兰

ALKERAN片剂适用于多发性骨髓瘤姑息治疗和卵巢不可切除上皮癌的姑息治疗。...

硼替佐米
硼替佐米

用于多发性骨髓瘤患者的治疗,此患者在使用本品前至少接受过两种治疗,并在最近一次治疗中病情还在进展。 用于复发或难治性...

艾曲博帕
艾曲博帕

PROMACTA是一种血小板生成素受体激动剂,用于治疗: 成人血小板减少症患者和一岁以上儿童慢性免疫性(特发性)血小板减少症(...

伊马替尼资讯
印度伊马替尼的价格
印度伊马替尼的价格

伊马替尼对慢性白血病和胃肠道间质瘤疗效非常好,它能为大多数可以负担该药物且能够遵守治疗,并且得到最佳治疗的慢性里细胞...

伊马替尼治白血病
伊马替尼治白血病

第一代酪氨酸激酶抑制剂伊马替尼对CML的治疗具有重要价值,而干扰素α是TKI药物诞生前CML治疗的一线药物...

伊马替尼耐药,该怎样解决
伊马替尼耐药,该怎样解决

达沙替尼用于治疗成人甲磺酸伊马替尼耐药或不耐受费城染色体阳性(P H)慢性髓系白血病(CML)慢性、加速和急性变性(急性和急...

伊马替尼的副作用,怎么解决?
伊马替尼的副作用,怎么解决?

伊马替尼问世以来,许多慢性粒细胞性白血病患者接受了伊马替尼治疗,但在用药过程中出现了不同程度的不良反应,有时甚至需要...

长期使用伊马替尼要注意这些
长期使用伊马替尼要注意这些

伊马替尼是治疗慢性粒细胞白血病的有效药物,但需要长期使用。许多慢性粒细胞白血病患者担心长期服用伊马替尼,会给身体带来...

伊马替尼的用法和注意事项
伊马替尼的用法和注意事项

伊马替尼的临床上的常用药物,主要用于白血病的治疗,那么伊马替尼的效果怎么样?用法用量是多少呢?有哪些是需要注意的?...

伊马替尼给肿瘤患者带来希望
伊马替尼给肿瘤患者带来希望

伊马替尼是国际上公认代替干扰素治疗CML-CP(慢性期)的一线治疗方案,让CML的治疗进入了分子靶向治疗的时代。慢性粒细胞白血病...

伊马替尼治白血病?
伊马替尼治白血病?

伊马替尼是一种常用于治疗白血病的药物。因为很多人对它并不真正了解或害怕它的“副作用”,所以对它有一些怀疑和误解。...

格列卫的副作用
格列卫的副作用

白血病是一种血液病,也称为血癌,治疗非常困难。骨髓移植是一种方法,但患者往往选择其他治疗方法,因为他们找不到合适的骨...

伊马替尼的作用
伊马替尼的作用

伊马替尼片剂是一种不会经常碰触的药物,因为它是白血病和骨髓发育不良的药物。但是,有些患者对这个药品还是有些疑惑。...

伊马替尼视频
什么是白血病?
什么是白血病?

白血病是一类造血干细胞恶性克隆性疾病...

宝宝得了白血病还有救吗?
宝宝得了白血病还有救吗?

宝宝得了白血病不光有救,也有可能完全治愈,...

儿童白血病如何治疗?
儿童白血病如何治疗?

儿童白血病的治疗原则为早期诊断、早期治疗,有间歇、交替用药的方式,并坚持长期的治疗,预防复发。...

药房目录大全

Pharmacy Catalogue